Capitalization 60.95B 8.39B 65.54B 11.58B P/E ratio 2024 *
P/E ratio 2025 * 1,054x
Enterprise value 56.4B 7.77B 60.64B 10.72B EV / Sales 2024 *
EV / Sales 2025 * 5.66x
Yield 2024 *
Yield 2025 * 0.01%
More valuation ratios * Estimated data
Dynamic Chart
Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy MT
Innovent Biologics, Inc. and IASO Biotechnology Enhance Strategic Collaboration in Cell Therapy CI
Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc. CI
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China DJ
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions CI
Innovent Biologics, Inc Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer CI
Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer CI
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting CI
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting CI
Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA CI
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug MT
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 CI
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer CI
More news
1 day-1.47%
1 week+1.00%
Current month+9.38%
1 month+9.38%
3 months+11.34%
6 months+14.51%
Current year-5.85%
More quotes
1 week
Extreme 39.95
1 month
Extreme 35.45
Current year
Extreme 28.3
1 year
Extreme 27.3
3 years
Extreme 18.06
5 years
Extreme 18.06
10 years
Extreme 14
More quotes
Insider TitleAgeSince
Chief Executive Officer 61 11-04-27
President - 20-10-14
Chief Tech/Sci/R&D Officer - 20-10-31
Insider TitleAgeSince
Chief Executive Officer 61 11-04-27
Director/Board Member 80 15-10-17
Director/Board Member 65 17-06-04
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.47%+1.00%+22.71%-52.14% 8.52B
-0.56%+0.82%+16.21%+5.76% 99.82B
+4.13%+7.16%+18.05%-1.12% 43.57B
+0.88%-0.74%-18.18%-31.72% 32.66B
+0.96%+3.57%+79.99%+64.44% 29.9B
+0.06%-0.22%-3.36%+9.20% 16.03B
+1.29%+2.09%+5.05%-13.77% 14.8B
+0.28%-2.10%+2.63%-46.67% 11.92B
+6.84%+11.54%+592.83%+323.90% 10.93B
-0.81%+7.58%+43.05%+76.20% 9.38B
Average +1.17%+2.56%+75.90%+33.41% 27.75B
Weighted average by Cap. +0.94%+1.93%+40.83%+16.63%
See all sector performances


Ratios2024 *2025 *
Net sales 7.63B 1.05B 8.2B 1.45B 9.97B 1.37B 10.71B 1.89B
Net income -845M -116M -909M -161M 52.05M 7.17M 55.96M 9.89M
Net Debt -5.12B -706M -5.51B -973M -4.58B -631M -4.93B -871M
More financial data * Estimated data
Logo Innovent Biologics, Inc.
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
More about the company
Date Price Change Volume
24-07-24 40.25 $ -1.47% 5 379 099
24-07-23 40.85 $ -3.20% 4,384,940
24-07-22 42.20 $ +4.07% 7,042,472
24-07-19 40.55 $ -0.49% 5,105,452
24-07-18 40.75 $ -0.97% 1,810,217

Delayed Quote Hong Kong S.E., July 24, 2024 at 04:08 am

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target